Tim Demuth
Basel, BS, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 21, 2016
Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 08, 2016
A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer.
Journal: Cancer discovery
Published: July 18, 2016
An accessible pharmacodynamic transcriptional biomarker for notch target engagement.
Journal: Clinical pharmacology and therapeutics
Published: July 22, 2015
Combination therapy using Notch and Akt inhibitors is effective for suppressing invasion but not proliferation in glioma cells.
Journal: Neuroscience letters
Published: October 22, 2012
Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: May 02, 2012
Targeting radiation-induced G(2) checkpoint activation with the Wee-1 inhibitor MK-1775 in glioblastoma cell lines.
Journal: Molecular cancer therapeutics
Published: October 14, 2011
Showing 1-8 of 8
Last Updated: 09/26/2026